Exonate Limited

Exonate Ltd, based in Cambridge, UK, is a large, active company founded eleven years ago in December 2013. Employing fifteen people and holding £2,529,105 in assets, it’s a significant player despite having no officially reported owners. The company operates from a real address and is overseen by seven directors. It’s an irregular importer, primarily dealing in miscellaneous chemical products, with its last import activity recorded eleven months ago.

The company’s website highlights its mission to transform the lives of those suffering from vision loss. Exonate is a biotechnology company focused on developing small molecule drugs to treat retinal vascular diseases, with its lead asset, EXN407, poised for Phase IIb clinical trials in 2024. The website details its pipeline, awards, and investor opportunities, emphasizing its focus on alternative mRNA splicing to combat angiogenesis – a key driver of disease progression. It also features a team page and a contact form, indicating a focus on building relationships and attracting investment.

Financially, Exonate Ltd presents a mixed picture. While turnover remains undisclosed, current assets have plummeted by nearly 54%, dropping from £5.5 million to £2.5 million. This decrease is mirrored in net assets, which have fallen by a staggering 180%, reaching -£4 million. Cash reserves have also taken a hit, decreasing by 50% to £2 million. However, administrative expenses have significantly reduced by 35%, suggesting cost-cutting measures. Interest payable has increased by 98%, which could be a result of increased borrowing to support research and development. The company’s auditor is Ensors Accountants LLP. It's worth noting that the company is small, meeting two of three criteria for turnover under £36 million, assets under £18 million, and fewer than 250 employees.

Registered in England/Wales under the registration number 08803638, with a registered address at CB22 4PS, England, Cambridge, Cambridgeshire, Wtl Moorfield Road, Duxford.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.